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DELAYED VS. IMMEDIATE PROGENITOR CELL CRYPORESERVATION
J. Ayello, C. Hesdorffer, M. Semidei-Pomales, R. Reiss
Divisions of Transfusion Medicine and Medical Oncology, Herbert Irving
Comprehensive Cancer Center, Columbia University, New York, NY
Harvesting of peripheral blood progenitor cells (PBPC) is sched-
uled according to the patient’s white cell or CD34 cell count.
Immediate cryopreservation of PBPC products may not be possi-
ble. Storage at 4C for 12–24 hours is an alternative. Engraftment
data of such PBPC products was compared with those cryopre-
served immediately following collection.
Patients with high risk stage II/III or metastatic breast cancer
were mobilized with chemotherapy and G-CSF and leukapheresed
daily until the desired number of CD34 cells were collected. Har-
vests completed after 6:00 pm were stored overnight and then cry-
opreserved. PBPC products stored for 12 hours from 15 patients
were compared with cells that were cryopreserved immediately fol-
lowing collection from another 15 patients. All products were
frozen according to standard protocols in a 5% DMSO, 6% HES,
and 4% HSA solution and stored at 90°C until the time of trans-
plantation. The posttransplant time to recovery of ANC >1000/L
and platelets >20,000/L was determined.
The median number of MNC/kg and CD34 cells/kg reinfused
into patients receiving PBPC products stored overnight and those
receiving PBPC immediately cryopreserved was similar (3.29 vs.
3.99108, and 2.56 vs. 2.41106, respectively). No differences in
median days to ANC >1000/L and platelets >20,000/L was noted
(9 vs. 9 and 11 vs. 11, respectively).
PBPC products stored at 4C for 24 hours before cryopreserva-
tion allows for appropriate prompt engraftment that is comparable
with PBPC cryopreserved immediately.
THE EXCELLENT OUTCOME IN CHILDREN WITH ULTRA HIGH-RISK
FEATURES (UHRF) OF ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN
FIRST REMISSION (CR) FOLLOWING MATCHED RELATED ALLOGENEIC
BMT (ALBMT)
M.S. Cairo, H. Sather, K. Schultz, F. Ozkaynak, L. Sender, N. Heere-
ma, J. Stehbens, J. Sanders, M. Trigg
Children’s Hospital of Orange County, Orange, CA; Children’s Cancer
Group (CCG), Arcadia, CA
Children with acute lymphoblastic leukemia (ALL) in first remission
(ISTCR) with ultra high-risk features (UHRF) including: t(9;22) (q34;q11);
bcr-abl; t(4;11) (q21;q25) or 11q23; 44 chromosomes, induction failure, or age
	10 years and WBC 	200 K/mm3, have a poor prognosis with conventional
chemotherapy (30% 4-year EFS). CCG initiated a clinical trial in children
with ALL and at least one of the above UHRF had a matched related donor.
Twenty-three patients who met the eligibility criteria and had a matched (6/6
or 5/6 serology) sibling/parental donor underwent myeloblative therapy 1200
cGy TBI (200 cGy BID  3), CTX 60 mg/kg  2, GVHD prophylaxis with
MTX (days 1, 3, 6, and 11) and CSP. Median age was (125 
 12.9 months),
M/F 15:8, 17 patients with abnormal cytogenetics (9 PH), 4 delayed induction
and 2 increased AGE/WBC. Although there was 48% incidence of grade IV
mucositis, the regimens were otherwise well tolerated with only one toxic death
(4%). The 3-year EFS for all children with ALL and the UHRF was 61 
11%. In the subset of patients with PH (t9;22) ALL, the CR 3-year EFS was 65
 17%. (In all children with cytogenetic abnormalities, the 3-year EFS was 49

 13%.) In the remainding 6 children with UHRF, the 3-year EFS was 100%.
In a group of children identiﬁed with similar UHRF ALL in ﬁrst CR with a
matched related ALBMT donor who did not receive an ALBMT on this pro-
tocol had a signiﬁcantly inferior outcome (36 
 13% vs. 61 
 11%, 3-year
EFS, p  0.04). Similarly, in children with cytogenetic abnormalities in ALL in
ﬁrst CR with matched related donors who did not receive ALBMT on this
protocol, the prognosis was extremely dismal (0% vs. 49 
 13%, 3-year EFS, p
 0.003). In summary, children with the UHRF ALL in ﬁrst CR appear to
have an improved outcome (DFS) following matched related ALBMT com-
pared with previous historical experience with conventional chemotherapy.
HEPATITIS B SEROCONVERSION AFTER DONOR LYMPHOCYTE INFUSION
Frank Beardell, Janet Brunner, Frederick Garbrecht, Dolores Grosso,
Jose Martinez, Scott Murphy, Stephen Schuster, Neal Flomenberg
Thomas Jefferson University Hospital, Philadelphia, PA
The use of donor lymphocyte infusion (DLI) after allogeneic BMT has been
shown to be an effective therapy for patients with relapsed CML, AML, and
multiple myeloma (MM).
The following describes a 48-year-old woman with primary refractory myeloma
originally diagnosed in March 1994. She initially received VAD therapy followed
by high-dose cyclophosphamide and dexamethasone. In October 1994, there was
evidence of progression. Allogeneic BMT from her HLA-identical, Hep B
seronegative brother was carried out in December 1994. She was conditioned
with busulfan and cyclophosphamide and received a T cell-depleted BMT. In
March 1995, increased liver transaminases and alkaline phosphatase were noted.
Ultrasound exam demonstrated an enlarged liver with fatty inﬁltration vs. early
ﬁbrosis. Hepatitis C virus studies were negative. Hepatitis B virus workup demon-
strated surface antigenemia, as well as core antibody reactivity. In May 1995, per-
sistent surface antigenemia and Hep B virus ampliﬁcation on PCR was demon-
strated. Evaluation of the patient’s MM showed less than 5% bone marrow
plasma cells. However, a low level serum M-protein persisted. In September 1996,
a liver biopsy demonstrated chronic hepatitis with normal portal architecture. The
portal tracts contained mild, acute, and chronic inﬂammatory inﬁltration with
mild piecemeal necrosis. Rare foci of lobular inﬂammation with rare hepatocellu-
lar dropout was noted. Ground glass hepatocytes were not seen. In November
1996, the patient had a substantial increase of her serum M-protein. Donor lym-
phocyte infusion from her original donor was administered on December 12,
1996. A marked decrease in the serum M-protein and bone marrow plasma cells
was demonstrated. Serial Hep B serology demonstrated a loss of surface antigen,
persistent core antibody without surface antibody reactivity. Over the next 34
months, the PCR study became negative and the transaminases normalized. In
April 1997, progressive MM was noted. A second DLI was performed. In October
1997, seroconversion to Hepatitis B surface antibody was demonstrated. The
patient remains PCR negative for the Hepatitis B virus at this time. M-protein
remains in the serum.
The efﬁcacy of DLI in the management of hematologic malignancies post-
BMT has been clearly demonstrated. To our knowledge, this is the ﬁrst report of
seroconversion of chronic Hepatitis B after the infusion of donor lymphocytes.
SEQUENTIAL ADMINISTRATION OF GM-CSF PRIOR TO AND OVER-
LAPPING WITH G-CSF ENHANCES THE COLLECTION EFFICIENCY OF
CD34 CELL YIELD POST-CHEMOTHERAPY (CH), COMPARED WITH
G-CSF POST-CH, AND SUBSTANTIALLY DECREASES THE COST OF
STEM CELL COLLECTION
Emanuel Cirenza, Carol Duma, Barbara Maloy, Scott Menzie
Albany Medical Center (AMC), Albany, NY
We performed a retrospective analysis of 74 patients who underwent periph-
eral blood stem cell (PBSC) collection at AMC before planned HDC with
PBSCT. All patients underwent at least one collection cycle (deﬁned as 1–5
collections post-CH plus growth factor mobilization). Patients with HD (9),
NHL (13), MM (3), Br CA (45), Ov CA (2), brain tumor (l), and CA (1) were
included in our analysis. We utilized the CH program in which patients were
enrolled. Post-CH patients were apheresed after being administered G-CSF
5 g/kg/day sc on day 7 through day 15 (n=41), or GM-CSF qam 5
g/kg/day on day 5 through day 12, and G-CSF 5 g/kg/day sc qpm on day
8 through day 15 (n=33). Leukapheresis began after the WBC increased to

3.0  109/L and daily for 4 or 5 days. Our goal was to collect 1.0  107
CD34 cells/kg. We transplanted patients with 	4.0  106 CD34 cells/kg.
For patients whose nadir did not fall to 2.0  109/L, leukapheresis began
when the WBC count increased to 	10.0  109/L.
Cytokine Total Avg. # # Coll. to reach (CD34 cells/kg  106)
# coll./ 	2.0 	5.0 	7.5 	10.0
coll. patient % pts. obtaining cell yield*
G-CSF 165 4.02 1.51 2.20 2.66 4.02
(n=41) 100* 92.5* 82.9* 78.0*
GM-/G-CSF 62 1.88 1.15 1.16 1.38 1.88
(n=33) 100* 100* 100* 96.2*
Savings/patient ($) 258 3108 4113 7717
The above calculations (savings/patient) included the costs of G- and
GM-CSF (retail) and apheresis/processing at our institution ($4,000/collec-
tion). We conclude that sequential GM-/G-CSF mobilization realizes sub-
stantial savings for CD34 collections 	5.0  106/kg.
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SECOND DONATION REQUESTS SUBMITTED TO THE NATIONAL MARROW
DONOR PROGRAM® (NMDP): ANALYSIS OF RECIPIENT OUTCOMES
Dennis Confer, Jolene Splett, Roberta King, Craig Kollman, 
Craig W.S. Howe
NMDP, Minneapolis, MN
Through January 1997, the NMDP had facilitated over 5,500
unrelated donor marrow transplants (TX). In 265 instances (5%), a
request for additional marrow (M, 146 [55%]) or for peripheral
blood stem cells (PBSC, 119 [45%]) was submitted. One hundred
seventy-eight requests (67%) were for graft failure (GF), 78 (29%)
were for relapse (REL), and 9 (3%) were for other reasons. The
median time from initial TX to request was 2.2 months (0–56).
The median age of patients was 25.9 years (1.3–59.9). Among the
265 patients, the request was ultimately resolved by infusion of a
second product (INF, 117 [44%]) or by cancellation (CA, 148
[56%]). Cancellation occurred at the discretion of the transplant
center (e.g., changing patient condition) or at the discretion of
NMDP (i.e., product unobtainable). At a median follow-up of 18
months (3–58), the Kaplan-Meier estimate of survival for all 265
patients was 22% 
 4%. Survival was not affected by patient age,
patient diagnosis, or request resolution (INF vs. CA). Among 117
patients infused, 76 (65%) received M, 40 (34%) received PBSC,
and 1 received both. Survival in this group was unaffected by stem
cell source (M vs. PBSC) or by indication (GF vs. REL). We con-
clude that outcomes among these high-risk patients, including
those receiving a second stem cell infusion, are encouraging. Inves-
tigations to improve these results are warranted.
AUTOLOGOUS STEM CELL RESCUE FOR HIGH-RISK CENTRAL NER-
VOUS SYSTEM TUMORS: PHASE I STUDY OF CYCLOPHOSPHAMIDE,
CARBOPLATIN, AND MELPHALAN
Reggie E. Duerst, J. Liesveld, A. Rapaport, C. Abboud, A. Billett
University of Rochester, Rochester, NY
The prognosis of patients with central nervous system (CNS) malig-
nancies that recur or progress despite conventional surgery, radiation
therapy, and chemotherapy has been very poor. The role of high-dose
chemotherapy followed by hematopoietic stem cell rescue (HSCR) has
been examined at several centers utilizing combinations of BCNU,
cyclophosphamide (CY), carbobplatin (CB), thiotepa, etoposide, and/or
melphalan (LPAM). Improvements in long-term responses are needed.
We evaluated the combination of CY (1800 mg/m2  2), CB
(400–800 mg/m2  2) and LPAM (140 mg/m2  1) followed by
HSCR (autologous marrow or peripheral blood stem cells) in a
Phase I study with dosage escalation of CB. CB was increased in 100
mg/m2/dose increments with at least 4 patients treated at each
dosage level. Twenty-three patients (ages 3–23 years) have been
treated with this regimen. All patients had recurrent, progressive, or
persistent disease despite radiotherapy (50–70 Gy) to the primary
tumor. Histology of the tumors included: 10 edulloblastoma/primi-
tive neuroectodermal tumor, 6 glial tumors (4 glioblastoma multi-
forme), 3 ependymal tumors, 2 pinealblastoma, and 1 each of germ
cell tumor and choroid plexus carcinoma. There were 2 deaths relat-
ed to toxic complications of the therapy. Of 15 evaluable patients,
complete response was seen in 2, partial response in 2, and mixed
response in 1. Eleven patients are surviving (8 without recurrence)
1–78 months post-HSCR (median 24 months). Thirteen patients
experienced recurrence (10 within 10 months of HSCR); 3 patients
had progression-free periods of 23, 24, and 58 months.
The combination of CY, CB, and LPAM has demonstrated efﬁca-
cy for some patients with high-risk CNS tumors. A phase III study of
this cytoreduction regimen followed by HSCR will evaluate its safety
and efﬁcacy in a larger group of CNS tumor patients.
EFFECT OF TRANSPLANTATION OF FACILITATOR CELLS ON ENGRAFT-
MENT OF ALLOGENEIC STEM CELLS
Nagwa El-Badri-Dajani, Robert A. Good
University of South Florida All Children’s Hospital, St. Petersburg, FL
The purpose of this research has been to investigate the role of
co-transplantation of puriﬁed osteoblasts (facilitator cells) along
with hematopoietic stem cells to prevent and/or treat the develop-
ment of autoimmune disease in an animal model for coronary vas-
cular disease, W/B F1 mice. W/B F1 is a strain of mice that spon-
taneously develops an occlusive coronary vascular disease,
thrombocytopenia, and systemic lupus-like syndrome. Previous
research has shown successful prevention and/or treatment of the
autoimmune disease in these animals by transplantation of healthy
bone marrow or crude stem cell preparations from partially
matched, but not fully allogeneic donors. Hematopoietic stem cells
puriﬁed as low-density, lineage-negative cells of bone marrow of
healthy BALB/c mice are co-transplanted along with osteoblasts
from the same donor into fully allogeneic, W/B F1 mice. The
transplanted mice are showing good survival and appear to be free
of autoimmune disease. The transplanted mice are currently ana-
lyzed for immunological functions and manifestations of autoim-
mune disease, including renal and cardiac pathology, and
antiplatelet antibodies. Results of our experiments should add to
understanding the biology of stem cell disorders and the role of
stem cells in the development of autoimmune disease.
A PHASE I TRIAL OF DOUBLE TRANSPLANT FOR METASTATIC BREAST
CANCER: SEQUENCE AND INTERVAL CONSIDERATIONS
A.D. Elias, C. Wheeler, P. Richardson, E. Reich, P. Hu, D. Avigan, 
C. Bunnell, G. Demetri, R. Joyce, J. Levine, D. Warren, B. Teicher, 
L. Ayash, E. Frei III
Harvard Medical School, Boston, MA
Despite high complete-response rates, single-cycle high-dose ther-
apy in women with metastatic breast cancer responding to conven-
tional dose induction chemotherapy results in approximately 20%
3-year and 16% 5-year event-free survival. New strategies are need-
ed to improve long-term outcomes. One such approach is to increase
dose intensity using double transplant regimens. Critical design
issues include the elimination of lengthy induction chemotherapy,
which may induce drug resistance and the use of different agents for
each transplant cycle. Since June 1994, we have enrolled 47 women
with metastatic breast cancer into one of two consecutive phase I
double transplant trials. Induction consisted of 2 cycles of doxoru-
bicin 30 mg/m2/day days 1–3 given every 2 weeks with G-CSF 5
g/kg sq days 4–12 for stem cell mobilization and collection. Trans-
plant regimen I consisted of CTCb (cyclophosphamide 6g/m2,
thiotepa 500 mg/m2, and carboplatin 800 mg/m2). Transplant regi-
men II consisted of a dose escalation of 24-hour infusion taxol from
100–475 mg/m2 followed by melphalan 90 mg/m2  2 doses. The
ﬁrst 32 patients received transplant regimen II followed by regimen I
5 weeks later; the remaining patients received the regimens in
reverse order. All patients completed both transplant cycles. No toxic
deaths occurred. Dose-limiting peripheral neuropathy was encoun-
tered at the 475 mg/m2 dose level of taxol, although it was largely
reversible. The degree of mucositis also appeared related to taxol
dose level. Event-free survival appears to be promising at one year.
This double transplant approach is feasible and tolerable. Treatment
duration is only 14 weeks and eliminates lengthy induction
chemotherapy. A randomized concept has been proposed to evaluate
single vs. double transplant and to study the relationship of acute
drug resistance to the timing of multicycle therapy. Preclinical mod-
eling and update response and survival will be presented.
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IL-11 PLUS G-CSF IS AN EXCELLENT CYTOKINE COMBINATION FOR
PERIPHERAL BLOOD PROGENITOR CELL (PBPC) MOBIL1ZATION IN CHIL-
DREN FOLLOWING IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE
(ICE) CHEMOTHERAPY
S. Goldman, I. Kirov, G. Davenport, C. van de Ven, V. Slone, M.S. Cairo
Children’s Hospital of Orange County, Orange, CA
We have found the combination of IL-11 plus G-CSF is safe in pediatric
patients with high-risk solid tumors receiving ICE chemotherapy and may
enhance platelet and myeloid recovery. During the conduct of this ongoing
phase I trial, ﬁve patients (pts) with a median age of 9 years (2–12) have under-
gone PBPC collection after their ﬁrst course of ICE, IL-11 plus G-CSF. Dx
were 3 CNS tumors (2 medulloblastomas [Med] and 1 anaplastic astrocytoma),
1 pt with relapsed metastatic Wilms, and 1 pt with refractory Hodgkin’s (Hd).
Patients received ICE (Ifos 1.8 gm/m2/d  5 days; Carbo 400 mg/m2/d  2
days; Etop 100 mg/m2/d  5 days) followed with G-CSF at 5 mcg/kg/d and
IL-11 at 50 mcg/kg/d (2 pts) or IL-11 at 100 mcg/kg/d (3 pts) through comple-
tion of PBPC collection(s). Patients began collection at a median of 21 days
(range 19–35) post–starting ICE chemotherapy. Mean WBC, ANC, and
platelet counts on collection day 1 were 12.5103/mm3, 8.8103/mm3, and
84,000/mm3, respectively. The mean and median numbers of CD34  106
cells/kg were 12.7 and 11.5, respectively. All patients achieved 5106 CD34
cells/kg between 1 and 3 days of collection, with a mean number of collections
of 1.8 days. Notably, all three patients receiving IL-11 at the 100 mcg/kg/d
achieved 5106 CD34 cells/kg in 1 day. The mean CD34/41 subsets of
PBPC in the latest two patients undergoing collection was 5.3106/kg. Two
patients (both received IL-11 of 50 mcg/kg for mobilization) have used their
stem cells in autologous transplantation after myeloablation. Preparative regi-
mens consisted of VP-16/BCNU/cytoxan in the patient with Hd and
cytoxan/thiotepa/carbo in a patient with Med. ANC recovery 500/mm3
occurred on day 14 and 10, respectively. Platelet recovery 20 k/mm3 untrans-
fused occurred on day 18 in the Hd patient, but could not be assessed in the
patient with Med because she was transfused to keep the platelet count 50
k/mm3. In conclusion, ICE chemotherapy followed with the combination of
G-CSF and IL-11 yields large numbers of CD34 cells, and preliminarily
extremely large numbers of platelet progenitors (CD34/41), and importantly
can effectively reconstitute hematopoiesis post–myeloablative chemotherapy.
G-CSF–MOBILIZED PERIPHERAL BLOOD CD34 CELLS BUT NOT
CD34 CELLS FROM NORMAL BONE MARROW SECRETE MATRIX
METALLOPROTEINASES (MMP-2 AND MMP-9)
Anna Janowska-Wieczorek, Maria Luisa Cabuhat, Leah Marquez
University of Alberta, Edmonton, Alberta, Canada
We investigated whether the matrix metalloproteinases such as
MMP-2 and MMP-9 (gelatinases A and B), which degrade type IV
collagen, are involved in the mechanism(s) of CD34 progenitor
cell mobilization. MMP-2 and MMP-9 secretion by CD34 cells
obtained from the peripheral blood (PB) of patients and donors
treated with G-CSF and from normal steady-state bone marrow
(BM) was evaluated. The CD34 cells were separated using Mil-
tenyi MiniMACS columns and incubated in serum-free media
either in the absence or presence of cytokines G-CSF, GM-CSF,
M-CSF, SCF, IL-3, IL-6, IL-8, TGF-, and TNF-; and the
cell-conditioned media were subjected to zymographic analysis.
We found that BM CD34 cells did not secrete either MMP-2 or
MMP-9, but acquired this ability upon G-CSF mobilization into
the PB. BM CD34 mononuclear cells secreted MMP-9 constitu-
tively. Cytokines such as GM-CSF, M-CSF, SCF, IL-3, IL-6,
IL-8, and TGF- induced secretion of both MMP-2 and MMP-9
in BM CD34 cells. However, in G-CSF–mobilized PB CD34
cells, GM-CSF, IL-6, and TGF- increased MMP-2 but not
MMP-9 production. Cytokines, which are used as mobilizing
agents (G-CSF, GM-CSF, SCF, and IL-3), induced MMP-2 and
MMP-9 production in steady-state BM CD34 cells but did not
upregulate these activities in already mobilized PB CD34 cells.
TNF- had the most stimulatory effect on MMP-2 and MMP-9
secretion by both BM and PB CD34 cells in a time- and
dose-dependent manner. These data suggest that the upregulation
of MMP-2 and MMP-9 production in CD34 cells could be impli-
cated in the mechanism of stem cell mobilization.
RISK FACTOR ANALYSIS FOR EPSTEIN-BARR VIRUS (EBV)-ASSOCIATED
B-CELL LYMPHOPROLIFERATIVE DISEASE (BLPD) FOLLOWING
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
Thomas Gross, Michael Steinbuch, Todd DeFor, Ralph Shapiro, 
John Kersey, Philip McGlave, Norma Ramsay, John Wagner, 
Alexandra Filipovich
University of Nebraska Medical Center, Omaha, NE
In this study, 26 cases of BLPD were identified from 2395
HSCT at the University of Minnesota (3/74–5/96). Analysis was
confined to the 1542 allogeneic HSCT because BLPD was not
seen following autologous HSCT. The factors assessed were
HLA-mismatching (	1 antigen), T-cell depletion (TCD), acute
GVHD (grade II–IV), donor type (related vs. unrelated), age of
recipient and donor, and underlying disease. Kaplan-Meier estima-
tion for incidence and Cox regression for relative risk (RR) were
performed. Overall incidence of BLPD in allogeneic HSCT 
2.0%. The incidence of BLPD among allogeneic HSCT was 8.1%
for patients transplanted for immune deficiency and 3.5% for
CML, 2.7% for donor age 	18 years, 7.2% for TCD, and 5.3%
for HLA-mismatching, with recipients of TCD and HLA-mis-
matched grafts having the highest incidence of 15.7%. All of these
factors were statistically signiﬁcant (p  0.01). Multivariate analysis
found TCD RR  5.4, immune deﬁciency RR  3.8, and donor
age (continuous variable) RR  1.04 to be statistically signiﬁcant (p
 0.01). Though immune deﬁciency was identiﬁed in the multi-
variate analysis as statistically significant, 5/6 of these patients
received a TCD graft from a haploidentical parent. The ﬁnding of
increased donor age as a risk factor was surprising and may reﬂect
increased EBV-positivity or perhaps poorer immune reconstitution
with these donors. These data fail to conﬁrm previous reports that
HLA-mismatching or GVHD by themselves are signiﬁcant risk
factors, but conﬁrm previous studies that TCD is the most signiﬁ-
cant risk factor for BLPD, especially in conjunction with
HLA-mismatching.
DONOR-DERIVED THY1 CELLS SUPPRESS GVHD AFTER DLI
Bryon Johnson, Emily Becker, Robert Truitt
Medical College of Wisconsin, Milwaukee, WI
Delayed infusion(s) of donor T cells following allogeneic BMT (often
referred to as DLI) have been given for the successful treatment of post-
transplant leukemia relapse. For unknown reasons, the incidence and severi-
ty of GVHD following DLI are less than expected considering the relatively
large numbers of T cells administered. Previous studies in our laboratory
using murine models of MHC-compatible and haplo-mismatched (parent
into F1) allogeneic BMT demonstrated that GVHD could be completely
avoided if administration of donor T cells was delayed until at least 3 weeks
posttransplant. Recently, we have used a full MHC-mismatched model
(C57BL/6 into AKR) to determine how increased immunogenetic disparity
impacts on GVH/GVL reactions following DLI. In contrast to the
MHC-matched model, GVHD was still observed when MHC-mismatched
donor T cells were infused 3 weeks posttransplant. Limiting dilution analy-
ses were done to determine the frequency of alloreactive CTL and IL-
2–secreting T helper cells in the spleens of mice 7 days after DLI treatment.
The presence of GVHD in the MHC-mismatched model correlated with
persistence of T-helper function. Delayed infusion of either puriﬁed CD4
or CD8 T cells 3 weeks posttransplant resulted in signiﬁcantly less GVHD.
No GVH-associated mortality was observed after DLI with puriﬁed donor
CD4 T cells. If the infusion of unseparated donor T cells was delayed 1
more week (4 weeks posttransplant), clinically evident GVH was completely
absent. Since non–T cell-depleted donor BM was used in these studies,
experiments were designed to assess whether BM-derived donor T cells
(Thy1.2) contributed to GVHD following DLI. AKR recipients were
given non–T-depleted C57BL/6 BM (day 0), treated or not treated in vivo
with depleting anti-Thy1.2 monoclonal antibody (days 10–12 post-BMT),
then given DLI with congenic B6.PL Thy1.1 T cells at various times post-
transplant. Compared with untreated mice, the anti-Thy1.2-treated mice
developed more severe GVHD following DLI as indicated by increased
mortality and body weight loss. These results suggest that donor-derived
Thy1.2 cells in the BM inoculum suppress GVH reactivity following DLI.
Studies are in progress to determine whether these suppressor cells are T
cells or non-T cells that express Thy1.
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LOW INCIDENCE OF ACUTE GRAFT-VS.-HOST DISEASE IN THAI
PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
S. Jootor, A.Ungkanont, S. Chuncharunee, S. Hongeng, S. Singhapakdi
Ramathibodi Hospital, Bangkok, Thailand
Acute graft-vs.-host disease (aGVHD) is a major cause of mor-
bidity and mortality during the ﬁrst few months after allogeneic
stem cell transplantation. The incidence of aGVHD varies from 30
to 70% in various trials. The incidence of aGVHD among oriental
patients seems to be lower than that of Westerners. We report here
the very low incidence of aGVHD among Thai patients after
unmodiﬁed HLA-matched BMT and PBSCT. From June 1989 to
December 1997, 26 patients received HLA-identical BMT and 28
patients received HLA-identical PBPC. The diseases for which the
patients were transplanted were leukemias, severe aplastic anemia,
and thalassemia. The conditioning regimens were either
buaulfan/cycloplosphamide or cyclophosphamide/TBI. Posttrans-
plant immunosuppressive treatment consisted of Cy A and short
methotrexate. Ten patients (18.5%) developed grade I aGVHD
and nine patients (16.6%) developed grade II–IV aGVHD. The
reason for the lower incidence of aGVHD in oriental patients is
uncertain. There is no major difference in patient selection, condi-
tioning regimen GVHD prophylaxis, and diagnosis of GVHD
between our study and other centers in Western countries. It is
postulated that a lower degree of genetic disparity might play an
important role in our ﬁnding.
IMPROVED LYMPHOCYTE AND CD34 CELL RECOVERY IN BONE
MARROW MONONUCLEAR CELLS PREPARED WITH THE COBE SPECTRA
Carolyn Keever-Taylor, Ann Cook-Craig
Medical College of Wisconsin, Milwaukee, WI
Whole marrow must be depleted of red blood cells, plasma, and granulo-
cytes for infusion into ABO incompatible recipients or as a necessary step in
other processing procedures. Density gradient media (DGM) designed for the
enrichment of blood mononuclear cells has been most commonly used for this
purpose. Here we compare results from 109 procedures in which DGM was
used to prepare marrow mononuclear cells with those from 43 procedures
using the Cobe Spectra Cell Processor (Spectra). In each case, the mononu-
clear cells were further processed to remove mature T lymphocytes by com-
plement-mediated lysis with T10B9 mAb. Cell counts were performed and
lymphocytes, monocytes, and CD34+ cells were measured using ﬂow cytome-
try. T cell depletion (TCD) was compared using a limiting dilution assay. The
results are summarized below.
Total cells* LY** CD34 Log Deplete
Spectra 28 
 11% 47 
 14% 3.8 
 1.6% 1.5 
 0.4
DGM 25 
 10% 27 
 2% 1.7 
 0.9% 1.7 
 0.4
p value 0.10 0.05 0.0000 0.06
*Percent recovery from whole marrow.
**Percent of the cell preparation.
Nucleated cell recovery was not different; however, lymphocyte, monocyte
(not shown), and CD34 cell content was signiﬁcantly higher in Spectra-
processed marrow. Spectra-processed components contained 87.1 
 33.2% of
lymphocytes  monocytes along with 93.1 
 18.9% of the starting marrow
CD34 cell content. TCD was somewhat lower for Spectra processed mar-
rows, prompting us to increase the concentration of T10B9 used in the purging
procedure to compensate for the increased porportion of starting T cells. The
hematocrit was consistently 5% in Spectra processed components vs. 0.5%
in DGM components. These data show superior recovery of CD34 cells,
improved enrichment of mononuclear cells, and adequate depletion of red
blood cells using the Cobe Spectra, which additionaly avoids the use of
reagents not approved for marrow processing.
ALLOGENEIC BONE MARROW TRANSPLANTATION (ALLOBMT) IN
MYELODYSPLASTIC SYNDROMES (MDS): WAYNE STATE UNIVERSITY
EXPERIENCES
C. Karanes, E. Abella, V. Ratanatharathorn, W. Du, A. Akhtar, 
J. Klein, R. Dansey, L. Sensenbrenner, R. Baynes
Barbara Ann Karmanos Cancer Institute, Wayne State University,
Detroit, MI
During October 1988 and July 1997, 62 patients underwent alloBMT
at the Detroit Medical Center for MDS. Ten of 62 (16%) cases were
therapy-related MDS. Median age was 42.5 years. Forty-four patients
received alloBMT from related donors (2 from daughters, 1 from a
mother) and 18 patients received bone marrow from unrelated donors.
Ten patients received one antigen mismatched bone marrow. The
preparative regimen was busulfan, ara-c, cyclophosphamide in 58
patients. GVHD prophylaxis included cyclosporine  methylpred-
nisolone (32), cyclosporine  methotrexate ([mtx] 20) and FK506  mtx
(5). Bone marrow cytogenetics were normal in 22 patients, 15 had single
abnormality, and 18 had complex abnormalities. The status at BMT
were RA, 2; RARS, 6; RAEB, 19; RAEB-t, 9; AML, 11; hypoplastic
MDS, 7; and unclassiﬁed, 7. Thirty-four of 62 patients (54.8%) are alive
and in complete remission (54.5% related alloBMT and 55% unrelated).
The 2-year relapse rate was 16%. There was no difference between
patients who received related or unrelated BMT in regard to day 100
mortality rate or relapse rate. All but one of the relapsed patients were
able to achieve remission after discontinuation of immunosuppressive
drugs. Some patients (25.8%) died within 100 days of BMT. The major
cause of death before day 100 included infections (37.5%), multiorgan
dysfunction (25%), acute GVHD (18.75%), and veno-occlusive disease
(12.5%). For patients who survived beyond day 100, 26% died with
relapse as the major cause of death in 8 of 12 patients. Of those still alive,
20% developed extensive GVHD. The 2-year overall survival and
event-free survival rates were 55 and 52% with the median follow-up of
22.3 months. The 2-year event-free survival for patients with normal
BM cytogenetics statistically is signiﬁcantly better than for patients with
single or complex abnormalities (75 vs. 40%, p  0.01) There was no
difference in overall survival or event-free survival in patients among dif-
ferent subclasses of MDS. 
INTENSIVE INDUCTION PROGRAM PRECEDING TANDEM AUTOLO-
GOUS BMT FOR BREAST CANCER—AN INTENTION-TO-TREAT STUDY
A. Langleben, S. Burdette-Radoux, M. Trudeau, D. Fitchett, S. Huttner,
B. DeSalis, B. Leyland-Jones
McGill University Hospital Centre, Montreal, Quebec, Canada
Supported by Susan Leader and Lynda Turner Research Funds
In an attempt to increase the proportion of patients responding to
induction chemotherapy before being assigned to high-dose thera-
py and stem cell support, ultra high-dose epirubicin (200 mg/m2 in
9 patients, 250 mg/m2 in 11 patients) has been administered to 20
(of a planned 40) patients with stage IIIB or IV breast cancer. EPI
is given by continuous infusion (CI) over 4 days, with ADR 529 at a
6:1 ratio by simultaneous CI. MTX 200 mg/m2 i.v. is given on day
4, and 5 FU 500 mg/m2 i.v. is given on day 5 with G-CSF and stem
cell support on cycles 2 to 6. Six such cycles are given before
responders proceed to tandem high-dose alkylating agent–based
autologous transplantation. (BMT regimen #1; cytoxan 150 mg/kg,
CisPlat 165mg/m2, melphalan 120 mg/m2, EPI 120 mg/m2. BMT
regimen #2, cytoxan 5625 mg/m2, platinum 165 mg/m2, BCNU
500mg/m2). Total maximum EPI dose is 1500 mg/m2 before BMT
# 1; complete biopsy-proven cardioprotection is achieved. Toxicity
is substantial but manageable. Survival data are presented below.
Response after EPI Induction
Complete 4
Partial 9
Minor 4
Progressive disease 2
Toxic death 1
Total 20
100
19
2018
17
REPEATED CYCLES OF ULTRA HIGH-DOSE EPIRUBICIN-BASED
CHEMOTHERAPY WITH STEM CELL SUPPORT—SUFFICIENT BUT LIMITED
NUMBERS OF STEM CELLS CAN BE HARVESTED TO SUPPORT THIS
TYPE OF APPROACH
A. Langleben, B. Morin, P. Laneuville, S. Burdette-Radoux, 
M. Trudeau, B. DeSalis, B. Leyland-Jones
Departments of Medicine and Oncology, McGill University Hospital
Centre, Montreal, Quebec, Canada
Supported by the Lynda Turner and Susan Leader-Fenster Funds
Six cycles of high-dose chemotherapy have been given to 20 (of a
planned 40) patients with stage IIIB or IV breast cancer. Doses are
epirubicin 200 mg/m2 per cycle (in 9 patients) and 250 mg/m2 per
cycle (in 11 patients) by continuous infusion over 4 days, with all
patients receiving MTX 200 mg/m2 on day 4 and 5 FU 500 mg/m2
on day 5. Upon completion of each cycle of chemotherapy, patients
receive G-CSF 5 mcg/kg  3 days, then 10 mcg/kg  6 days, and
then 5 mcg/kg until completion of harvest of PBSC. PBSC are har-
vested for 5 days upon count recovery during cycles 1, 2, and 3 and
are reinfused after cycles 2, 3, 4, 5, and 6 and two subsequent high-
dose alkylator-based treatments. Consistent white count and
CD34 count recovery occur by day 18 (day 0 is initiation of
chemotherapy), peak at day 19, and fall by day 22. However, the
CD34/kg/day count collected decreases from 1.5107 post–ﬁrst
cycle to 0.6107 post–second cycle to 0.3107 post–third
cycle, suggesting that the number of CD34 cells that can be
mobilized is limited even with sequential autotransplantation. Clin-
ically, neutrophil counts recover by day 16, and platelets by day 17
in all patients in each of the six cycles.
ACTIVATED T CELLS (ATC), IL-2, AND GM-CSF AFTER PBSCT FOR
ADVANCED BREAST CANCER (PHASE I/II)
L.G. Lum, J. Treisman, R.F. Taylor, A.V. LeFever
St. Luke’s Medical Center, Milwaukee, WI
High relapse rates after PBSCT for advanced breast cancer are
the rationale for adoptive immunotherapy strategies to eradicate
residual tumor and improve survival. Patients (10 stage IV, 1 stage
IIIB) received combination chemotherapy followed by G-CSF–
primed PBSC. After PBSCT, patients received: 1) 8 doses of
10109 ATC twice a week for 3 weeks followed by 6 doses of
20109 ATC/week; 2) continuous infusion IL-2 (3105
IU/m2/day) starting on day 1 and ending on day 65; and 3)
GM-CSF (250 g/m2/day SQ) starting on day 5 until an ANC of
1500/mm3 was reached, followed by 125 g/m2/day until day 21.
ATC were grown in RPMI 1640 using 20 ng/mL OKT3, 100
IU/mL IL-2, and human serum for up to 17 days. The median %
(
SD) positive cells for speciﬁc phenotypes was 98 (2) CD3, 58
(23) CD4, 45 (24) CD8, 95 (3) CD45RO, and 7 (18) CD25.
Non-MHC restricted cytotoxicity was present, and cells produced
Th1 and Th2 cytokines. ATC-related toxicities included only 1
grade 4 (G4  1) transient thrombocytopenia. Other toxicities
included: chills (G1  2; G2  1), skin rash (G3  3; G1  1),
vomiting and diarrhea (2), stomatitis (G1, G2  1 each), muscle
aches (G2  1), fever (G1, G2, G3  1 each) anemia (1), neurosen-
sory/motor deﬁcits (G1, G2, G3  1 each), and GVHD-like rash
(3). Toxicities did not preclude completing infusions totaling
200109 ATC/patient. There were no delays in engraftment.
Seven of 11 patients are disease-free (day 10 to day 427) after
PBSCT. ATC with IL-2, GM-CSF, and PBSCT was well tolerat-
ed and could be effective in treating advanced breast cancer.
VENO-OCCLUSIVE DISEASE (VOD) OF THE LIVER FOLLOWING BONE
MARROW TRANSPLANTATION (BMT): ANALYSIS OF RISK FACTORS AND
RESULTS OF THERAPY WITH TISSUE PLASMINOGEN ACTIVATOR (TPA)
M. Litzow, P. Repoussis, G. Schroeder, D. Schembri-Wismayer, 
K. Batts, P. Anderson, C. Arndt, D. Gastineau, M. Gertz, D. Inwards,
M. Lacy, A. Tefferi, P. Noel, L. Solberg Jr, L. Letendre, H. Hoagland
Mayo Clinic, Rochester, MN
We reviewed our BMT database between April 1982 and July 1996 and
identiﬁed 111/474 patients with serum bilirubin (SBR) 	2.0 mg/dL for 2
consecutive days within the ﬁrst 20 days post–related allogeneic (allo) or
autologous (auto) BMT. Seventy-eight of 111 fulﬁlled the Seattle criteria
for VOD (2 of the 3 following characteristics: SBR 	2.0 mg/dL,
hepatomegaly, or weight gain 22%). Five were excluded because of the
presence of obvious fungal infection pre- or post-mortem as a cause for
their liver dysfunction. Fourteen of 73 patients had autoBMT (6% of all
autoBMT in this period) and 59of 73 had alloBMT (26% of all alloBMT).
Fifty-six of 73 received TBI as part of the conditioning regimen (1320
cGy). Fifty of 59 alloBMT patients received a methotrexate (MTX)-con-
taining graft-vs.-host disease (GVHD) prophylaxis regimen. Twenty-eight
(38%), 12 (16%), and 33 (45%) patients had severe (unresolved or dead of
VOD by day 100), moderate (required therapy), or mild (self-limited and no
therapy) VOD by Seattle criteria. In 20 of 23 patients, liver biopsy or autop-
sy conﬁrmed a diagnosis of VOD. None of the 23 patients with maximum
(max) SBR 	15 mg/dL survived, all patients with max SBR 7.5 mg/dL
survived, and 7 of 15 (47%) patients with SBR 7.5–15 mg/dL survived. In
univariate and multivariate logistic regression analyses, the only pretrans-
plant risk factor predictive of severe VOD was advanced disease state (p 
0.035). Transplant factors predictive of severe VOD in univariate analysis
included maximum SBR, hepatomegaly, meeting the Baltimore criteria for
VOD, and multiorgan dysfunction. The only signiﬁcant transplant factors
for VOD in multivariate analysis were maximum SBR (p  0.01) and maxi-
mum blood urea level (p  0.03). Ten patients (all with creatinine 	1.7
mg/dL) were treated with tPA (doses 10–50 mg for 2–4 days) and heparin,
with only 2 patients demonstrating a signiﬁcant response and only 1 surviv-
ing beyond day 120. We conclude that the risk of VOD is signiﬁcantly
increased in BMT patients with advanced disease pretransplant and that the
max SBR is a strong predictor of outcome. In our experience, tPA was inef-
fective at reversing severe VOD.
REMISSION OF REFRACTORY SEZARY SYNDROME AFTER MATCHED
UNRELATED DONOR MARROW TRANSPLANTATION
Arturo Molina, Auayporn Nademanee, Margaret O’Donnell, 
Daniel Arber, David Senitzer, Stephen J. Forman
City of Hope National Medical Center, Duarte, CA
Bone marrow transplantation (BMT) from a matched unrelated
donor was performed in a young patient with refractory Sezary syn-
drome (SS) to see if this treatment modality would be effective
against this rare disorder. The patient was a 12-year-old girl in 1986
when she presented with erythrodermic follicular mucinosis, leuko-
cytosis, hypereosinophilia, adenopathy, pulmonary inﬁltrates, circu-
lating Sezary cells, and immunologic/genotypic evidence of a clonal
T-cell disorder. A skin biopsy showed a perifollicular cellular inﬁl-
trate composed of abnormal helper T cells. Subsequently, she failed
treatment with prednisone (PRED), methotrexate (MTX), PUVA,
photopheresis, and hydroxyurea. In 1994, because of progressive dis-
ease, she had a lymph node biopsy which showed SS/T-cell lym-
phoma (NHL) with clonal cytogenetic abnormalities, and was start-
ed on alpha-interferon (-IFN). After two years of -IFN, she was
treated with a cycle of cladarabine (2-CDA). Before BMT in August
1996, she had persistent SS with erythrodermic skin disease,
adenopathy, and bone marrow (BM) involvement. The preparative
regimen was FTBI and cyclophosphamide. GVHD prophylaxis con-
sisted of MTX, cyclosporine (CSA), and PRED. She recovered from
all acute BMT-related toxicities, and a day 30 BM biopsy showed
disappearance of the SS with complete male donor engraftment. Her
posttransplant course has been complicated by mild chronic skin
GVHD, which is improving with CSA/PRED. Staging studies per-
formed 100 days and 1 year post-BMT showed no evidence of recur-
rent SS/T-cell NHL—her ﬁrst durable remission since her initial
diagnosis 11 years ago. To our knowledge, this is the ﬁrst patient
with refractory SS who has been successfully treated with unrelated
donor BMT. Our results indicate that this modality may be effective
in inducing remission in refractory SS.
